Key precautions include hepatotoxicity monitoring, gallbladder events, statin interactions, and hepatic impairment avoidance.

Risk Mitigation and Monitoring Protocols

Hepatotoxicity: Monitor liver enzymes (ALT, AST, bilirubin) and symptoms (jaundice, fatigue). Discontinue if drug-induced liver injury is suspected. Gallbladder-related events (cholelithiasis, cholecystitis) require diagnostic evaluation; interrupt treatment for acute events. Statin interactions: Limit atorvastatin/pravastatin to 40 mg daily and rosuvastatin/simvastatin to 20 mg daily. Avoid use in moderate-severe hepatic impairment (Child-Pugh B/C). Hypersensitivity reactions (rash, urticaria) and thyroid hormone changes (↓ FT4) require clinical vigilance.